Requires insurance companies to prove that a healthcare service or procedure is not medically necessary.
Summary
H5862 amends Rhode Island’s Benefit Determination and Utilization Review Act by creating a new rule for medical necessity determinations in health insurance coverage. Under the bill, if a healthcare provider authorizes a healthcare service or procedure for a patient, that authorization would create a presumption that the service is medically necessary.
The practical effect is to shift the burden to the insurance company when it wants to deny coverage: the insurer would have to provide justification for any denial of a provider-authorized service or procedure. The bill applies broadly to healthcare services and procedures and would take effect immediately upon passage.
Impact
This bill would add a new section to chapter 27-18.9 of the Rhode Island General Laws, altering how utilization review and benefit determinations are handled by health insurers. It would not eliminate denials, but it would require insurers to substantiate them when a provider has already authorized treatment, potentially affecting claims review practices, prior authorization disputes, and coverage appeals. The main parties affected would be health insurance companies, healthcare providers, and insured patients seeking medically necessary care.
Sentiment
The available record shows no committee transcript or recorded votes, so there is no documented debate or formal vote history to gauge support or opposition. Based on the bill text and caption, the measure appears designed to favor patients and providers by making coverage denials harder to sustain, suggesting a consumer-protection orientation. However, without discussion or votes, the level of legislative support or concern cannot be determined from the provided materials.
Contention
The central point of contention would likely be the shift in burden from patients and providers to insurers. Supporters would likely view the bill as a way to reduce unjustified denials and strengthen access to care, while opponents may argue it limits insurer discretion, increases costs, or weakens utilization review controls. No specific individuals, committees, or stakeholder positions are documented in the provided context.